Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial

NCT02103296 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this protocol is to establish a randomized clinical trial comparing the use of cord blood vs. infant blood with the primary outcome of comparing both the absolute hemoglobin concentration and the percent change in hemoglobin concentration from baseline around 24 hours of life.

Conditions Studied

Interventions

  • PROCEDURE Drawing admission labs from cord blood
  • PROCEDURE Drawing admission labs from infant blood

Study Locations (6)

Texas

  • Carl R. Darnall Army medical Center — Fort Hood
  • San Antonio Military Medical Center — Fort Sam Houston

Hawaii

  • Tripler Army Medical Center — Honolulu

Maryland

  • Walter Reed National Military Medical Center — Bethesda

Virginia

  • Portsmouth Naval Medical Center — Portsmouth

Washington

  • Madigan Army Medical Center — Tacoma

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-02
Est. Completion 2021-07-25
Phase NA

Sponsor

Capt Alicia Prescott

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02103296

The ClinicalTrials.gov registry entry for NCT02103296 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capt Alicia Prescott, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions — of which Drawing admission labs from cord blood is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02103296 reports 6 study locations spanning 5 distinct geographic areas — top geographies include Texas, Hawaii, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02103296 about?

NCT02103296 is a clinical study titled "Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial". The goal of this protocol is to establish a randomized clinical trial comparing the use of cord blood vs. infant blood with the primary outcome of comparing both the absolute hemoglobin concentration and the percent change in hemoglobin concentration from baseline around 24 hours of life.

What is the current status of trial NCT02103296?

This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2014-02. Estimated completion is 2021-07-25.

What conditions does trial NCT02103296 study?

This clinical trial studies the following conditions: Anemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02103296?

The interventions under investigation include: Drawing admission labs from cord blood (PROCEDURE), Drawing admission labs from infant blood (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02103296?

This trial is sponsored by Capt Alicia Prescott, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02103296 being conducted?

This trial has 6 study locations across Hawaii, Maryland, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial